Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,2,5,6-dianhydrogalactitol
2. 1,2-5,6-dianhydrogalactitol
3. Dianhydrogalactitol
4. Diepoxydulcitol
5. Diepoxygalactitol
6. Nsc 132313
7. Nsc-132313
8. Nsc132313
1. 1,2:5,6-diepoxydulcitol
2. Dianhydromannitol
3. 23261-20-3
4. 1,2-bis(oxiran-2-yl)ethane-1,2-diol
5. Nsc 132313
6. 5,6-diepoxydulcitol
7. 1,2-5,6-dianhydro-dulcitol
8. 1,2:5,6-dianhydrodulcitol
9. Galactitol, 1,2:5,6-dianhydro-
10. Dianhydrodulcitol;dianhydrogalactitol
11. Nsc132313
12. 19895-66-0
13. Nsc-133129
14. 1,6-diepoxydulcitol
15. 1,6-dianhydrodulcitol
16. 1,6-dianhydromannitol
17. 1,6-dianhydrogalactitol
18. 1,6-diepoxy-d-mannitol
19. 1,6-dianhydro-d-mannitol
20. 1,2:5,6-dianhydrohexitol
21. 1,6-di-anhydro-d-mannitol
22. Galactitol,2:5,6-dianhydro-
23. Schembl8375579
24. D-mannitol,2:5,6-dianhydro-
25. Chembl1987719
26. Dtxsid60941768
27. Mannitol,2:5,6-dianhydro-, D-
28. Nsc133129
29. Akos025396866
30. Nci60_000711
31. Ft-0667810
32. 261d203
Molecular Weight | 146.14 g/mol |
---|---|
Molecular Formula | C6H10O4 |
XLogP3 | -1.3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 146.05790880 g/mol |
Monoisotopic Mass | 146.05790880 g/mol |
Topological Polar Surface Area | 65.5 Ų |
Heavy Atom Count | 10 |
Formal Charge | 0 |
Complexity | 122 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 4 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?